Citadel Advisors’s Aligos Therapeutics ALGS Stock Holding History

Citadel Advisors’s Portfolio ALGS Stock Details ALGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-56	Closed	-$490	–	14160
2024 Q2	$490	Sell	56 -96	-63%	-$1.69K	﹤0.01%	13979
2024 Q1	$3.72K	Buy	+152	New	+$3.03K	﹤0.01%	13873
2023 Q3	–	Sell	-188	Closed	-$4.56K	–	14227
2023 Q2	$4.56K	Sell	188 -316	-63%	-$8.47K	﹤0.01%	13587
2023 Q1	$11K	Buy	504 +220	+77%	+$8.41K	﹤0.01%	13491
2022 Q4	$6.77K	Buy	+284	New	+$7.16K	﹤0.01%	13884
2022 Q1	–	Sell	-616	Closed	-$183K	–	13490
2021 Q4	$183K	Buy	+616	New	+$225K	﹤0.01%	11977

Other funds holding ALGS

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

SummitTX Capital Fort Worth, Texas $3.2B AUM 41.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Citadel Advisors's ALGS Position: Q1 2026 in Review

Citadel Advisors increased its Aligos Therapeutics (ALGS) stake by 4.8% in Q1 2026, buying an estimated $18.8K and bringing the position to 54,311 shares worth $404K. The position accounts for ﹤0.01% of the portfolio, ranked #9800.

Citadel Advisors first reported a position in ALGS in Q2 2021 and has held it in 14 quarters since. The position peaked at $483K in Q4 2025. 35 funds tracked by Wall St. Rank hold ALGS as of Q1 2026.

Citadel Advisors held 54,311 shares of Aligos Therapeutics worth $404K as of Q1 2026.
Citadel Advisors bought 2,477 Aligos Therapeutics shares in Q1 2026, an estimated $18.8K.
Aligos Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #9800 holding.
Citadel Advisors first reported a position in Aligos Therapeutics in Q2 2021 and has held it in 14 quarters since.
Citadel Advisors's Aligos Therapeutics position peaked at $483K in Q4 2025.
35 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.